Share Prices & Company Research

Market News

29 Jan 2021 | 13:24

Johnson and Johnson Covid-19 vaccine 85% effective against severe illness

(Sharecast News) - Drugmaker Johnson & Johnson reported topline efficacy and safety data from a Phase three clinical trial on its single-dose Covid-19 vaccine on Friday, stating the drug had met all primary and key secondary endpoints. Johnson & Johnson said topline safety and efficacy data, based on 43,783 participants accruing 468 symptomatic cases of Covid-19, indicated a single dose was 85% effective at preventing severe illnesses and 66% effective in preventing both moderate and severe diseases.

No major side effects from the vaccine were reported, including severe allergic reactions.

Chief executive Alex Gorsky said: "Johnson & Johnson embarked on the global effort to combat the Covid-19 pandemic a year ago, and has brought the full force of our capabilities, as well as tremendous public-private partnerships, to enable the development of a single-shot vaccine. Our goal all along has been to create a simple, effective solution for the largest number of people possible, and to have maximum impact to help end the pandemic.

"We're proud to have reached this critical milestone and our commitment to address this global health crisis continues with urgency for everyone, everywhere."

However, the vaccine's efficacy against a variant of Covid-19 originating in South Africa was seen as somewhat of a concern after Moderna stated its vaccine appeared to be less effective against the variant and a study from Pfizer also suggested a less robust response.

Johnson & Johnson, which developed the vaccine in conjunction with Janssen Pharmaceuticals, will apply for emergency use authorisation from the Food and Drug Administration as early as next week.

As of 1350 GMT, Johnson & Johnson shares were down 3.59% in pre-market trading at $163.08 each.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.